Neurocrine Biosciences, Inc. v. Crystal Pharmaceutical (Suzhou) Co., Ltd. et al
Crystal Pharmatech Co., Ltd. |
Neurocrine Biosciences, Inc. |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
1:2021cv01464 |
October 18, 2021 |
US District Court for the District of Delaware |
Maryellen Noreika |
Patent - Abbreviated New Drug Application(ANDA) |
35 U.S.C. § 271 |
None |
Docket Report
This docket was last retrieved on December 13, 2021. A more recent docket listing may be available from PACER.
Document Text |
---|
Pro Hac Vice Attorney C. Kyle Musgrove for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (smg) |
Filing 9 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Crystal Pharmatech Co., Ltd. for Crystal Pharmaceutical (Suzhou) Co., Ltd. filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Phillips, John) |
Filing 8 ANSWER to #1 Complaint, Affirmative Defenses, COUNTERCLAIM against Neurocrine Biosciences, Inc. by Crystal Pharmaceutical (Suzhou) Co., Ltd..(Phillips, John) Modified on 12/10/2021 (mdb). |
Pro Hac Vice Attorney Scott A. Cunning, II for Crystal Pharmaceutical (Suzhou) Co., Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
|
|
Filing 7 MOTION for Pro Hac Vice Appearance of Attorney Scott A. Cunning II, C. Kyle Musgrove and Elizabeth M. Crompton - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Bilson, David) |
Filing 6 STIPULATION Regarding Waiver of Service and Establishment of Answer Deadline for Defendant Crystal Pharmaceutical (Suzhou) Co., Ltd., by Neurocrine Biosciences, Inc.. (Balick, Steven) |
Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (nms) |
Filing 5 Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (twk) |
Filing 4 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,993,941; 11,026,931; 11,026,939; 11,040,029. (twk) |
Filing 3 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received First Notice: September 7, 2021. Date of Expiration of the 941 Patent: October 10, 2037. Date of Expiration of the 931 Patent: August 14, 2039. Date of Expiration of the 029 Patent: October 10, 2037. Date of Expiration of the 939 Patent: September 18, 2038. (twk) |
Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
Filing 1 COMPLAINT FOR PATENT INFRINGEMENT filed against Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3723489.) - filed by Neurocrine Biosciences, Inc.. (Attachments: #1 Exhibit A-D, #2 Civil Cover Sheet)(twk) |
No Summons Issued. (twk) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.